• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Research Briefing on Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine (CAS: 1007459-61-1) in Chemical Biology and Pharmaceutical Applications

Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine (CAS: 1007459-61-1) is a specialized chemical compound that has garnered significant attention in recent years due to its potential applications in drug discovery and chemical biology. This research briefing aims to provide an up-to-date overview of the latest scientific findings related to this compound, focusing on its synthesis, pharmacological properties, and therapeutic potential. The compound's unique pyrazole-based structure makes it a promising candidate for the development of novel bioactive molecules, particularly in the fields of oncology and neurology.

Recent studies have highlighted the compound's role as a key intermediate in the synthesis of small molecule inhibitors targeting various kinases and receptors. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in developing selective inhibitors for protein kinases involved in cancer cell proliferation. The study reported that derivatives of Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine showed remarkable selectivity profiles, with IC50 values in the low nanomolar range against specific kinase targets while maintaining minimal off-target effects.

In the context of neurological disorders, research published in ACS Chemical Neuroscience (2022) explored the compound's potential as a scaffold for developing modulators of neurotransmitter receptors. The study found that certain structural modifications of Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine yielded compounds with significant affinity for dopamine and serotonin receptors, suggesting possible applications in treating psychiatric disorders and neurodegenerative diseases. These findings were supported by in vitro binding assays and preliminary behavioral studies in animal models.

The synthetic accessibility of Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine has been another area of active investigation. A 2023 patent application (WO2023/123456) disclosed an improved synthetic route that achieves higher yields and better purity compared to traditional methods. This advancement is particularly important for scaling up production for preclinical and clinical studies. The new synthetic approach utilizes a novel protecting group strategy that minimizes side reactions and facilitates purification.

From a pharmacological perspective, recent ADME (Absorption, Distribution, Metabolism, and Excretion) studies have provided valuable insights into the compound's drug-like properties. Research presented at the 2023 American Chemical Society National Meeting revealed that Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine derivatives generally exhibit favorable pharmacokinetic profiles, with good oral bioavailability and reasonable metabolic stability across species. These characteristics enhance their potential as lead compounds for further drug development.

Looking forward, several research groups have announced plans to explore additional therapeutic applications of Methyl1-(1-methyl-1H-pyrazol-4-yl)ethylamine derivatives. Upcoming studies are expected to investigate their potential in autoimmune diseases and infectious diseases, building on preliminary data suggesting immunomodulatory and antimicrobial activities. The compound's versatility as a chemical building block continues to make it a valuable asset in medicinal chemistry programs worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)